- Home
- YOSH vs CALC Comparison
YOSH vs CALC Comparison
Compare YOSH & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- CALC
- Stock Information
- Founded
- YOSH 2016
- CALC 2011
- Country
- YOSH United States
- CALC United States
- Employees
- YOSH N/A
- CALC N/A
- Industry
- YOSH Restaurants
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- CALC Health Care
- Exchange
- YOSH Nasdaq
- CALC Nasdaq
- Market Cap
- YOSH 23.7M
- CALC 22.9M
- IPO Year
- YOSH 2022
- CALC N/A
- Fundamental
- Price
- YOSH $9.69
- CALC $1.61
- Analyst Decision
- YOSH
- CALC Strong Buy
- Analyst Count
- YOSH 0
- CALC 3
- Target Price
- YOSH N/A
- CALC $16.33
- AVG Volume (30 Days)
- YOSH 5.6K
- CALC 29.8K
- Earning Date
- YOSH 08-18-2025
- CALC 08-11-2025
- Dividend Yield
- YOSH N/A
- CALC N/A
- EPS Growth
- YOSH N/A
- CALC N/A
- EPS
- YOSH N/A
- CALC N/A
- Revenue
- YOSH $13,539,317.00
- CALC N/A
- Revenue This Year
- YOSH N/A
- CALC N/A
- Revenue Next Year
- YOSH N/A
- CALC N/A
- P/E Ratio
- YOSH N/A
- CALC N/A
- Revenue Growth
- YOSH 41.82
- CALC N/A
- 52 Week Low
- YOSH $2.71
- CALC $1.42
- 52 Week High
- YOSH $22.50
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- YOSH 34.47
- CALC 46.35
- Support Level
- YOSH $9.19
- CALC $1.42
- Resistance Level
- YOSH $10.00
- CALC $1.85
- Average True Range (ATR)
- YOSH 0.76
- CALC 0.15
- MACD
- YOSH -0.16
- CALC -0.00
- Stochastic Oscillator
- YOSH 14.44
- CALC 41.86
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.